Engene Therapeutics Inc (ENGN) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Jul 31 2026 to Jul 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Engene Therapeutics Inc   (NASDAQ: ENGN)


Engene Therapeutics Inc's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Engene Therapeutics Inc's ROI in the third quarter of 2026?
Engene Therapeutics Inc recorded a cumulative net loss of $-10 million during 12 months ending in the third quarter of 2026, resulting in a negative return on investment (ROI) of -4.46%.

Within the Healthcare sector 216 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jul 31 2026 quarter, so far to 260, from total ROI ranking in the second quarter of 2026 at 3152.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jul 31 2026)
III. Quarter		 (Apr 30 2026)
II. Quarter		 (Jan 31 2026)
I. Quarter		 (Oct 31 2025)
IV. Quarter		 (Jul 31 2025)
III. Quarter
Y / Y Investment Change TTM -13.55 % -18.77 % -22.01 % 8.32 % 57.68 %
Y / Y Net Income Change TTM - 80.86 % - - 204.57 %
Investment (TTM) in Millions 261 288 192 192 227
Return On Investment (TTM) -4.46 % 22.76 % -2.28 % -4.14 % 15.98 %
ENGN's Overall Ranking # 260 # 3152 # 2907 # 422 # 751
Seq. Investment Change TTM 3.84 % 3.38 % -10.79 % -9.74 % -2.42 %
Seq. Net Income Change TTM - - - - 52.55 %
Net Income (TTM) in Millions -10 51 -5 -10 43

ENGN Company Profile >> Back to ENGN Roi Comparisons >> See Annual ENGN Return On Investment



Return On Investment ENGN's Ranking
Within: No.
Industry # 23
Sector # 217
Overall # 260

Return On Investment Statistics
High Average Low
24.8 %
10.93 %
-4.46 %
(Jan 31 2025)   (Jul 31 2026)







Financial Statements
Engene Therapeutics Inc's III. Quarter Investments $ 261 Millions ENGN's Balance sheet
Engene Therapeutics Inc's III. Quarter Income $ -33 Millions Quarterly ENGN's Income Statement
ENGN's Income by Division See ENGN's Income by Division


ENGN Annual Return On Investment (Oct 31 2025)
2025		 (Oct 31 2024)
2024		 (Oct 31 2023)
2023

Total Investments in Millions 189 297 82 0 0
Y / Y Investment Growth -36.09 % 262.92 % - - -
Net Income in Millions 117 55 110 0 0
Y / Y Net Income Growth 112.73 % -49.67 % - - -
Annual Return On Investment 61.9 % 18.6 % 134.1 % - -


Annual Roi Comment
In the fiscal year 2025 ROI improved to 61.9 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ENGN's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ENGN's Competitors
Subscribers only: Roi for Engene Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for ENGN's Customers

Other Ratios
ENGN's Roa ENGN's Inventory Turnover Ratio ENGN's Growth Rates ENGN's Dividend Statistics
ENGN's Profitability Ratios ENGN's Asset Turnover Ratio ENGN's Dividend Growth
ENGN's Roe ENGN's Valuation Ratios ENGN's Financial Strength Ratios ENGN's Dividend Payout Ratio



Companies with similar Return On Investment at Jul 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-10T01:27:28+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.